138 related articles for article (PubMed ID: 3486715)
1. Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.
Salup RR; Wiltrout RH
Cancer Immunol Immunother; 1986; 22(1):31-6. PubMed ID: 3486715
[TBL] [Abstract][Full Text] [Related]
2. Therapy of peritoneal murine cancer with biological response modifiers.
Salup RR; Herberman RB; Chirigos MA; Back T; Wiltrout RH
J Immunopharmacol; 1985; 7(4):417-36. PubMed ID: 3878855
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.
Salup RR; Wiltrout RH
Cancer Res; 1986 Jul; 46(7):3358-63. PubMed ID: 3486710
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.
Salup RR; Back TC; Wiltrout RH
J Immunol; 1987 Jan; 138(2):641-7. PubMed ID: 3491854
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
9. Influence of tumor site on the therapy of murine kidney cancer.
Chakrabarty A; Hillman GG; Maughan RL; Visscher DW; Ali E; Pontes JE; Haas GP
Anticancer Res; 1994; 14(2A):373-8. PubMed ID: 8017836
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy of malignant lymphoma with interleukin-2 and sizofiran--a basic study on EL-4 lymphoma-transplanted mice].
Hashimoto J
Nihon Jibiinkoka Gakkai Kaiho; 1994 Jul; 97(7):1235-49. PubMed ID: 8064508
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
Ann Ist Super Sanita; 1990; 26(3-4):423-32. PubMed ID: 2091504
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
13. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
Iigo M; Nishikata K; Nakajima Y; Moriyama M
Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic requirements for the successful treatment of murine renal carcinoma by adoptive chemoimmunotherapy.
Wiltrout RH; Mathieson BJ; Back TC; Salup RR
Prog Clin Biol Res; 1987; 244():17-25. PubMed ID: 3498946
[No Abstract] [Full Text] [Related]
15. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of murine mammary carcinoma using broadly cytotoxic cloned T lymphocytes.
Salup RR; Toth JA; Hiserodt JC; Wolmark N
Prog Clin Biol Res; 1987; 244():39-48. PubMed ID: 2958875
[No Abstract] [Full Text] [Related]
17. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.
Anderson TD; Hayes TJ; Gately MK; Bontempo JM; Stern LL; Truitt GA
Lab Invest; 1988 Nov; 59(5):598-612. PubMed ID: 3263543
[TBL] [Abstract][Full Text] [Related]
18. [Effect of biological response modifiers on a spontaneous murine renal cell carcinoma regression of metastases caused by the streptococcal preparation OK-432].
Tanji S
Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):716-25. PubMed ID: 1875566
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model.
Chakrabarty A; Hillman GG; Maughan RL; Ali E; Pontes JE; Haas GP
In Vivo; 1994; 8(1):25-31. PubMed ID: 8054507
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes.
Chen J; Niu H; He W; Ba D
Int Arch Allergy Immunol; 2001 Jul; 125(3):256-63. PubMed ID: 11490159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
